Tofacitinib Dosing Recommendation
For an adult patient without severe hepatic impairment or moderate-to-severe renal dysfunction, the recommended tofacitinib dose is disease-specific: 5 mg twice daily (or 11 mg extended-release once daily) for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; 10 mg twice daily (or 22 mg extended-release once daily) for ulcerative colitis induction therapy for 8 weeks, followed by 5 mg twice daily (or 11 mg extended-release once daily) for maintenance. 1
Disease-Specific Dosing
The most critical principle is that tofacitinib dosing must be tailored to the specific immune-mediated inflammatory disease being treated 2. This is not interchangeable between conditions.
Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
- Standard dose: 5 mg twice daily OR 11 mg extended-release once daily 1
- These doses are equivalent and can be used interchangeably based on patient preference 1
Ulcerative Colitis
- Induction phase: 10 mg twice daily OR 22 mg extended-release once daily for 8 weeks 1
- May extend to 16 weeks maximum if adequate response not achieved by week 8 1
- Maintenance phase: 5 mg twice daily OR 11 mg extended-release once daily 1
- For patients losing response during maintenance, may consider returning to 10 mg twice daily, but limit duration and carefully weigh benefits versus risks 2
The higher induction dose for ulcerative colitis reflects the need for more aggressive initial therapy in inflammatory bowel disease 3.
Key Dosing Principles
No dose adjustment is needed for:
- Mild hepatic impairment (Child-Pugh A) 3
- Mild renal impairment (CrCl 50-80 mL/min) 3
- Age, body weight, sex, or race 4
Since your patient lacks severe hepatic impairment or moderate-to-severe renal dysfunction, standard disease-specific dosing applies without modification.
Important Clinical Context
Drug Interactions Requiring Dose Reduction
If your patient is taking certain medications, dose adjustment IS required 2, 1:
- Strong CYP3A4 inhibitors (e.g., ketoconazole): Reduce to half the standard dose
- Moderate CYP3A4 inhibitor + strong CYP2C19 inhibitor (e.g., fluconazole): Reduce to half the standard dose
When to Increase Dose
Rifampicin (used for tuberculosis prophylaxis/treatment) increases tofacitinib metabolism, requiring dose increase consideration 2, 3.
Formulation Considerations
- XELJANZ (immediate-release) and XELJANZ XR (extended-release) are not interchangeable 1
- Switching between formulations should be done by the healthcare provider the day after the last dose of the previous formulation 1
- 5 mg twice daily immediate-release = 11 mg once daily extended-release
- 10 mg twice daily immediate-release = 22 mg once daily extended-release
Critical Safety Caveat
The 10 mg twice daily dose carries increased risks 3:
- Higher rates of serious infections, particularly in patients >65 years with cardiovascular risk factors
- Increased venous thromboembolism and pulmonary embolism risk
- Should only be used for ulcerative colitis induction or in select maintenance cases with loss of response
For rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, the 10 mg twice daily dose is not recommended due to these safety concerns 1.